URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers

Ding, Zhiwen; Pan, Yufei; Shang, Taiyu; Jiang, Tianyi; Lin, Yun‐Kai; Yang, Chun; Pang, Shujie; Cui, Xiaowen; Wang, Yixiu; Feng, Xiaofan; Xu, Mengyou; Pei, Mengmiao; Chen, Yibin; Li, Xin; Ding, Jin; Tan, Yexiong; Wang, Hongyang; Dong, Liwei; Wang, Lu

doi:10.1038/s41467-023-41852-z

Public

URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers

Published in Nature Communications • Oct 7, 2023

Authors:

Zhiwen Ding

Yufei Pan

Taiyu Shang

Abstract

The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited due to drug resistance. Here, we uncover that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5 interactor (URI) endows HCC with resistance t...

Subject

Cancer research

Reprogramming

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!